November 26, 2019
Takeda Pharmaceutical has reported a favorable update to its PIII ALTA-1L study for the ALK inhibitor Alunbrig (brigatinib), with the drug demonstrating better long-term outcomes versus Xalkori (crizotinib) in the first-line lung cancer setting. The study was conducted in over...read more